Beneficial effect of xylose consumption on postprandial hyperglycemia in Korean: a randomized double-blind, crossover design by unknown
RESEARCH Open Access
Beneficial effect of xylose consumption on
postprandial hyperglycemia in Korean: a
randomized double-blind, crossover design
Yun Ju Jun1†, Jinhee Lee2†, Sehee Hwang3, Jung Hyun Kwak4, Hyeon Yeong Ahn1,5, Youn Kyung Bak6,
Jihoon Koh6 and Jong Ho Lee1,5*
Abstract
Background: Previous studies have reported that xylose selectively inhibited the activity of sucrase. Xylose
supplementation may have a beneficial effect on the postprandial glycemic response. However, no studies
have investigated patients with IFG or the effectivity of a dose of D-xylose less than 10 % (w/w).
Methods: The present study determined the effect of xylose consumption on postprandial hyperglycemia in
normal (n = 25) and hyperglycemic subjects (n = 50). Subjects in this double-blind crossover design study were
randomly assigned to consume a sucrose drink (Control, sucrose 50 g + deionized water 100 g) or a sucrose drink
additionally containing 5 g (Test 1, sucrose:xylose = 10:1), 3.33 g (Test 2, sucrose:xylose = 15:1), or 2.5 g (Test 3,
sucrose:xylose = 20:1) of D-xylose separated by a one-week interval.
Results: Normal subjects in all test groups exhibited a significant decrease in serum glucose levels 15 min and
30 min after consuming the xylose-containing drinks compared to the control group. Significantly lower serum
levels of insulin were observed at 15 min and 30 min after consuming the xylose-containing drinks compared
to the control group. The test 1 group also exhibited a significantly lower insulin area under the curve than the
control group. Hyperglycemic subjects (n = 50) in all test groups exhibited a significant decrease in serum glucose
levels at 30 min compared to the control group. However, the test 1 group exhibited a significant increase in
serum glucose levels at 120 min compared to the control group. Glucose-related markers did not significantly
differ in each group.
Conclusion: Xylose supplementation may exert a beneficial effect on postprandial glycemic responses in subjects
with normal glucose levels and prediabetes.
Trial registration: ClinicalTrials.gov identifier: NCT02654301. Registered 12 January 2016.
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Background
Data from the 2010 Korea National Health and Nutri-
tion Examination Survey (KNHANES) reported that the
dietary total saccharide intake (61.4 g/day) increased by
23 % compared to the 2008 KNHANES report [1]. The
prevalence of impaired fasting glucose (IFG) in Koreans
aged greater than 30 years has also increased consist-
ently in the past three years [2–4]. Elevated postprandial
blood glucose (PPBG) has been associated with an in-
creased risk of metabolic disorders, type 2 diabetes, and
cardiovascular disease (CVD) [5]. Therefore, strategies
to reduce PPBG are very important.
Sugar is the most widely and commonly used sweet-
ener worldwide, and various sweeteners, such as sugar
alcohols, aspartame, and acesulfame potassium, were de-
veloped to substitute for sugar, the consumption of
which is a potential reason for the rise in obesity and
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diabetes rates [6]. However, sugar alcohols cause cramp-
ing, bloating, and diarrhea in excessive amounts [7], and
aspartame may be harmful to patients with phenylketon-
uria because of the generation of phenylalanine after
consumption [8]. Therefore, these alternative sweeteners
are limited as sugar substitutes.
Sucrase hydrolyzes sugar (sucrose) to glucose and
fructose, which are rapidly absorbed into the blood via
facilitated diffusion and active transport. Glucose ab-
sorption into the blood promotes insulin secretion,
which promotes blood glucose migration into cells, gen-
erates energy, or promotes storage in the liver and
muscle as glycogen [9]. However, the increase in blood
glucose by sugar intake may burden the pancreas of sub-
jects with IFG, and the consequent pancreatic damage
reduces insulin secretion [10].
Xylose is a naturally occurring monosaccharide that is
primarily found in wood, and D-xylose selectively in-
hibits sucrase activity. Therefore, D-xylose could prevent
the rise in blood glucose and insulin, which would also
decrease the burden on the pancreas [11].
Asano et al. reported that the consumption of a su-
crose drink containing 10 % (w/w) D-xylose suppressed
the rapid elevation of blood glucose and insulin in mice
[12]. A sucrose drink containing 10 % (w/w) D-xylose
also reduced the glycemic index (GI) by 21.4 % and insu-
lin secretion by 21.3 % in healthy individuals [13].
However, no studies investigated subjects with IFG
and the effectivity of a dose of D-xylose less than 10 %
(w/w). The current study assesses the acute effect of xy-
lose on postprandial glycemia in subjects with normal
glucose levels or prediabetics who consumed sucrose
drinks that contained 5 g (Test 1; sucrose:xylose = 10:1),
3.33 g (Test 2; sucrose:xylose = 15:1), or 2.5 g (Test 3;




We posted advertisements in the local newspaper to re-
cruit study subjects, and all clinical tests were conducted
in the Clinical Nutrition Research Laboratory at Yonsei
University. All study subjects aged 20 to 70 years were
classified into two groups, normal and IFG, based on
serum glucose levels. Subjects were excluded for the fol-
lowing reasons: 1) history of taking insulin injections or
oral hypoglycemic agents, 2) evidence of alcohol abuse
or alcoholism, 3) pregnant or breastfeeding, 4) chronic
gastrointestinal disorder, 5) seriously abnormal liver or
renal function, or 6) an occupation at risk of death when
hypoglycemia occurs. A fasting serum glucose level be-
tween 100 and 125 mg/dL was defined as IFG. Subjects
with fasting glucose levels over 126 mg/dL were newly
diagnosed with type 2 diabetes. The Institutional Review
Board of Yonsei University approved this study (IRB
163–02), and all participants provided written informed
consent. A total of 80 subjects were initially enrolled.
Two participants dropped out of the study for personal
reasons, and three participants discontinued the study
because they were terrified during blood collection. A
final total of 25 normal subjects and 50 hyperglycemic
subjects were analyzed in this study.
Study design
We adopted a randomized double-blind, crossover de-
sign to determine an effective proportion of D-xylose.
All study subjects were randomly assigned using the
random assignment table: for the consumption order of
four drinks provided by CJ Cheiljedang Co., Ltd. (Guro-
Gu, Seoul). The experimental drinks were indistinguish-
able from each other and included: 1) Control (sucrose
50 g + deionized water 100 g), 2) Test 1 (sucrose:xylose =
10:1, sucrose 50 g + xylose 5 g + deionized water 95 g), 3)
Test 2 (sucrose:xylose = 15:1, sucrose 50 g + xylose
3.33 g + deionized water 96.67 g), and 4) Test 3
(sucrose:xylose = 20:1, sucrose 50 g + xylose 2.5 g + de-
ionized water 97.5 g).
Subjects visited the Clinical Nutrition Research La-
boratory at Yonsei University for 4–5 weeks and ran-
domly ingested the four test drinks (Control, Test 1,
Test 2, and Test 3) with a one-week interval to avoid a
carryover effect, which is the persistence and influence
of the previous treatment on the following treatment in
a crossover design trial [14]. We also asked the subjects
to maintain their usual diet and physical activity until
the end of the study.
Anthropometric parameters, blood pressure
measurement, and blood collection
The body weight of barefoot subjects was measured
on the morning of each visit to obtain the body
mass index (BMI, kg/m2), which was calculated as
body weight (kg) divided by height squared (m2).
Body fat (%) was determined using a bioelectrical
impedance analyzer (InnerScan BC-533, Tanita,
Japan), and lean body mass (kg) was calculated using
weight (kg) and body fat (%). We also measured
waist circumference at the umbilical region and hip
circumference at the protruding part of the hip in
standing subjects.
Blood pressure (BP) was measured twice in the upper
arm after a 5-min rest using a non-invasive blood pres-
sure monitor (EASY X 800, Jawon Medical, Republic of
Korea). The average of two BP measurements was re-
corded. BP was measured a third time when the differ-
ence between the two BP measurements was greater
than 10 mmHg.
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Venous blood specimens were collected in EDTA-
treated and plain tubes at five time points: after fasting
for 12 h, and 15, 30, 60, and 120 min after the consump-
tion of each test drink. All blood samples were centri-
fuged to obtain plasma and sera, which were stored
in a −70 °C deep freezer until analysis.
Assessments of dietary intake and physical activity
We investigated subjects’ usual food intake using a 24-h
recall method and semi-quantitative food frequency
questionnaire (semi-FFQ) during their first visit and
instructed participants not to change their usual diet
and level of physical activity to avoid any effects on their
health and biochemical parameters.
Total calorie intake (TCI, kcal/day), the percentage of
calories from carbohydrates, protein, and fat, and the
amount of cholesterol in their diet (mg/day) were evalu-
ated using the Computer-Aided Nutritional analysis pro-
gram (CAN-pro 3.0, Korean Nutrition Society, Korea).
Total energy expenditure (TEE, kcal/day) was calculated
from the basal metabolic rate (BMR), the 24-h physical
activity [15], and the thermic effect of food (TEF). The
BMR of each subject was calculated using the Harris–
Benedict equation [16].
Fasting and postprandial glucose, insulin, C-peptide, and
FFA concentrations
Venous blood was drawn after a 12-h fast and 15, 30, 60,
and 120 min after the consumption of test drinks. The
hexokinase method colorimetrically measured NADP to
determine fasting and postprandial glucose concentra-
tions in sera using a clinical chemistry analyzer (Hitachi
7600 Autoanalyzer, Hitachi Ltd., Japan). Serum insulin
and C-peptide levels were analyzed using commercially
available radioimmunoassay (RIA) kits and a gamma
counter (Cobra Quantum 5002, Hewlett-Packard, USA).
Free fatty acids (FFAs) were measured using an enzym-
atic method involving acyl-CoA synthetase (ACS) and
acyl-CoA oxidase (ACOD).
Serum lipid profiles and apolipoproteins A-I and B
Fasting triglyceride and total cholesterol concentrations
(mg/dL) in sera were measured using enzymatic methods
in a clinical chemistry analyzer (Hitachi 7600 Autoanaly-
zer, Hitachi Ltd., Japan). High-density lipoprotein (HDL)
cholesterol (mg/dL) was analyzed in the supernatant using
selective inhibition methods after combination with chylo-
microns. Low-density lipoprotein (LDL) and very low-
density lipoprotein (VLDL) were combined with surfac-
tants. Low-density lipoprotein (LDL) cholesterol (mg/dL)
was estimated indirectly using the Friedewald formula.
Immunoturbidimetric methods were used to determine
serum apolipoproteins A-I and B (mg/dL) using a chem-
ical analyzer (Cobas Integra 400, Roche, Switzerland).
Safety parameters
The International Federation of Clinical Chemistry
(IFCC) recommends the measurement of serum glu-
tamic oxaloacetic transaminase (sGOT or AST) and
glutamic pyruvic transaminase (sGPT or ALT) using a
kinetic UV method and commercial kits (Roche,
Germany) on a chemical analyzer (Hitachi 7600 Autoa-
nalyzer, Hitachi Ltd., Japan). A kinetic UV assay and a
colorimetric method, specifically the Jaffe reaction,
were used to measure serum creatinine and blood urea
nitrogen (BUN), respectively.
A complete blood count (CBC) of white blood cells
(103/mm3), red blood cells (106/mm3), hemoglobin (g/
dL), hematocrit (%), and platelets (103/mm3) was per-
formed using a hematology analyzer (ABX Micros ES
60, HORIBA ABX Diagnostics, Inc., France).
Statistical methods
Statistical analyses were performed using SPSS version
18.0 for Windows (Statistical Package for Social Science,
SPSS Inc., USA). Each variable was examined for normal
distribution, and significantly skewed variables under-
went log transformation. The mean values of untrans-
formed variables are presented for descriptive purposes.
Baseline characteristics and comparisons between the
normal and hyperglycemic groups were evaluated using
Student’s t-test for continuous variables. Glucose, insu-
lin, and C-peptide areas under the curve (AUCs) were
calculated after subtraction of the baseline value from
each subsequent measurement using the trapezoidal
method [17]. Comparisons between the consumption of
the control drink (sucrose 50 g + deionized water 100 g)
and each test drink (Test 1: sucrose:xylose = 10:1, Test 2:
sucrose:xylose = 15:1, Test 3: sucrose:xylose = 20:1) were
evaluated using one-way analysis of variance (ANOVA)
and Bonferroni methods at each time point. Only results
from participants who completed the intervention pro-
gram were analyzed. The results are expressed as the
means ± standard error of the mean (SEM). We consid-
ered results with a p-value < 0.05 as statistically significant
and results with a p-value < 0.1 to exhibit a tendency to-
ward significance.
Results
Characteristics of normal and prediabetic subjects
Table 1 shows the general characteristics of the study
subjects. Hyperglycemic subjects were older (p < 0.001)
and had higher concentrations of triglycerides and Apo
B than normal subjects. Normal subjects exhibited a
higher TEE (kcal/d) than hyperglycemic subjects. There
were no significant differences between the two groups
in baseline characteristics, such as BMI, body fat, blood
pressure, HDL cholesterol, LDL cholesterol, Apo A-I,
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total energy intake, and the percent energy intake from
carbohydrate, protein, and fat.
Effects of xylose consumption on postprandial glucose
metabolism in normal subjects
Normal subjects (n = 25) in all test groups exhibited a
significant decrease in serum glucose levels at 15 min
(Test 1: 102.3 ± 2.39, Test 2: 104.1 ± 2.76, Test 3: 107.3 ±
2.81 versus Control: 120.8 ± 3.42 mg/dL) and 30 min
(Test 1: 113.8 ± 2.40, Test 2: 116.5 ± 2.84, Test 3: 118.2 ±
3.37 versus Control: 132.8 ± 3.74 mg/dL) than the con-
trol group (Fig. 1). However, normal subjects exhibited a
significant increase in serum glucose levels in all test
groups at 120 min compared to the control group. All
test groups also exhibited significantly lower serum
levels of insulin at 15 min (Test 1: 28.3 ± 5.19, Test 2:
24.8 ± 3.47, Test 3: 31.4 ± 4.05 versus Control: 56.6 ± 7.18
uIU/mL) and 30 min (Test 1: 30.4 ± 3.63, Test 2: 31.0 ±
3.59, Test 3: 35.9 ± 4.66 versus Control: 55.0 ± 5.21 uIU/
mL) than the control group (Table 2). The Test 1 group
exhibited significantly lower insulin AUC (Test 1: 46.2 ±
5.32 versus Control: 55.0 ± 5.21 uIU/mLxhr). We found
significantly lower serum levels of C-peptide at 15 min
(Test 1: 3.20 ± 0.31, Test 2: 3.26 ± 0.23 versus Control:
4.67 ± 0.39 ng/dL) and 30 min (Test 1: 4.41 ± 0.31 versus
Control: 6.01 ± 0.36 ng/dL) in the test groups compared
to the control group.






n (male/female) (13/12) (35/15)
Age (years) 28.2 ± 1.12 50.1 ± 1.80 <0.0001
Weight (kg) 69.5 ± 2.83 67.7 ± 1.48 0.053
BMI (kg/m2) 23.8 ± 0.72 24.4 ± 0.46 0.453
Body fat (%)a 25.1 ± 1.24 25.0 ± 1.07 0.742
Lean body mass (kg)a 52.1 ± 2.29 50.6 ± 1.18 0.672
Blood pressure (mmHg)
Systolic BP 119.2 ± 3.45 122.0 ± 2.08 0.470
Diastolic BPa 72.1 ± 2.38 74.4 ± 1.42 0.315
Lipids parameters
TG (mg/dL)a 92.3 ± 8.95 133.1 ± 11.58 0.010
T chol (mg/dL) 182.8 ± 6.32 196.4 ± 4.33 0.077
HDL chol (mg/dL) 57.4 ± 1.91 53.5 ± 1.43 0.108
LDL chol (mg/dL) 106.9 ± 5.26 116.5 ± 3.92 0.155
Apo A-I (mg/dL) 156.1 ± 3.52 149.7 ± 3.03 0.204
Apo B (mg/dL)a 90.5 ± 5.12 105.5 ± 3.19 0.014
Dietary intake and total energy expenditure
TEE (kcal/d) 2437 ± 70.8 2281 ± 37.5 0.036
TCI (kcal/d) 2315 ± 70.7 2272 ± 36.5 0.547
Carbohydrate (%) 61.7 ± 0.16 61.6 ± 0.11 0.558
Protein (%) 15.9 ± 0.08 15.9 ± 0.05 0.697
Fat (%) 23.1 ± 0.20 23.0 ± 0.15 0.812
Cholesterol (mg) 188 ± 0.50 186 ± 0.70 0.130
Mean ± SEM
aAnalyzed after log transformation; tested by Student t-test
Fig. 1 Serum glucose levels in normal subjects. Values are expressed
as the means ± SEM. p-value tested using one-way analysis of variance
(ANOVA) and Bonferroni methods
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Comparisons of changes in serum glucose, insulin, and C-
peptide levels in normal subjects
All test groups exhibited significantly lower changes in
serum glucose levels at 15–0 (Test 1: 17.4 ± 2.28, Test 2:
16.4 ± 2.23, Test 3: 20.5 ± 2.75 versus Control: 32.9 ±
3.24 mg/dL) and 30–0 (Test 1: 28.9 ± 2.07, Test 2: 28.8 ±
2.58, Test 3: 31.0 ± 3.03 versus Control: 44.9 ± 3.02 mg/
dL) compared to the control group (Fig. 2). We also found
significantly lower changes in serum insulin and C-
peptide levels at 15–0 and 30–0 compared to the control
group (data not shown).
Effects of xylose consumption on postprandial glucose
metabolism in hyperglycemic subjects
Hyperglycemic subjects (n = 50) in the test groups exhib-
ited a significant decrease in serum glucose levels at
30 min (Test 1: 149.6 ± 3.44, Test 2: 152.5 ± 3.56, Test 3:
158.8 ± 3.99 versus Control: 176.4 ± 5.18 mg/dL) com-
pared to the control group (Fig. 3). However, the Test 1
group exhibited a significant increase in serum glucose
levels at 120 min compared to the control group. The
glucose-related markers did not significantly differ be-
tween groups (Table 3).
Comparisons of changes in serum glucose, insulin, and
C-peptide levels in hyperglycemic subjects
The test 1 group exhibited a significantly lower change
in serum glucose levels at 15–0 (Test 1: 17.3 ± 2.11 ver-
sus Control: 27.4 ± 2.79 mg/dL), and all test groups ex-
hibited significantly lower changes in serum glucose
levels at 30–0 (Test 1: 39.4 ± 2.47, Test 2: 44.8 ± 2.48,
Test 3: 47.5 ± 2.55 versus Control: 66.5 ± 4.05 mg/dL)
Table 2 Glucose-related markers in normal subjects
Normal subjects (n = 25)
TEST (10:1) TEST (15:1) TEST (20:1) Control
Insulina 0 min 10.6 ± 0.98 9.8 ± 0.85 9.8 ± 0.71 9.3 ± 0.62
uIU/mL 15 min 28.3 ± 5.19c 24.8 ± 3.47c 31.4 ± 4.05c 56.6 ± 7.18b
30 min 30.4 ± 3.63c 31.0 ± 3.59c 35.9 ± 4.66c 55.0 ± 5.21b
60 min 25.8 ± 2.93 29.1 ± 2.35 24.9 ± 2.54 29.0 ± 3.05
120 min 14.0 ± 1.95b 12.0 ± 1.14 12.3 ± 1.04 9.4 ± 0.84c
Insulin AUCa (uIU/mLxhr) 46.2 ± 5.32c 46.8 ± 3.50 47.4 ± 3.77 62.4 ± 4.91b
C-peptidea 0 min 1.89 ± 0.17 1.92 ± 0.16 1.82 ± 0.15 1.92 ± 0.14
(ng/mLxhr) 15 min 3.20 ± 0.31c 3.26 ± 0.23c 3.44 ± 0.26 4.67 ± 0.39b
30 min 4.41 ± 0.31c 4.62 ± 0.32 4.82 ± 0.42 6.01 ± 0.36b
60 min 5.15 ± 0.31 5.36 ± 0.31 4.98 ± 0.28 5.70 ± 0.33
120 min 3.62 ± 0.22b 3.49 ± 0.24b 3.20 ± 0.21 2.69 ± 0.19c
C-peptide AUCa (ng/mLxhr) 8.36 ± 0.48 8.55 ± 0.47 8.23 ± 0.47 9.28 ± 0.50
Mean ± SEM. b,cTested by ANOVA (Bonferroni)
aAnalyzed after log transformation
Fig. 2 Comparisons of changes in serum glucose levels in normal
subjects. Values are expressed as the means ± SEM. p-value
tested using one-way analysis of variance (ANOVA) and
Bonferroni methods
Fig. 3 Serum glucose levels in hyperglycemic subjects. Values are
expressed as the means ± SEM. p-value tested using one-way analysis
of variance (ANOVA) and Bonferroni methods
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than the control group (Fig. 4). We also found signifi-
cantly lower changes in serum insulin and C-peptide
levels at 15–0 and 30–0 compared to the control group
(data not shown).
Safety parameters of normal and prediabetic subjects
Table 4 shows the safety parameters of study subjects.
Hyperglycemic subjects exhibited higher concentrations
of GOT and GPT than normal subjects. However, these
concentrations were within normal ranges.
Discussion
The present study determined the effects of xylose sup-
plementation on postprandial glycemic responses in
normal and hyperglycemic subjects. We investigated
whether D-xylose less than 5 g per 50 g sucrose exerted
beneficial effects on postprandial glycemic control. No
adverse biochemical effects of D-xylose were observed in
any subject during the entire study. We found that xy-
lose supplementation may exhibit beneficial effects on
postprandial glucose metabolism. Notable effects on
postprandial glucose, insulin, and C-peptide levels were
observed 15 and 30 min after the consumption of test
drinks.
Xylose is a white crystalline sugar that exhibits ap-
proximately 60 % of the sweetness of sucrose. Various
plants, including coconut and straw, are rich sources of
D-xylose [13]. Administration of a sucrose solution con-
taining 10 % D-xylose (w/w) inhibited the rapid eleva-
tion of blood glucose in rats [12]. Bae et al. reported
that the consumption of sucrose drinks containing 10 %
D-xylose (w/w) reduced GI 21.4 % and insulin secretion
21.3 % in healthy individuals [13]. Bae et al. reported on
Fig. 4 Comparisons of changes in serum glucose levels in
hyperglycemic subjects. Values are expressed as the means ±
SEM. p-value tested using one-way analysis of variance (ANOVA)
and Bonferroni methods






WBC (х103/uL) 5.59 ± 0.25 5.82 ± 0.18 0.468
RBC (х103/uL) 4.28 ± 0.08 4.33 ± 0.05 0.558
HGB (g/dL) 13.1 ± 0.37 13.4 ± 0.14 0.543
HCT (%) 40.7 ± 1.08 41.8 ± 0.42 0.382
PLT (х103/mm3) 256 ± 13.3 244 ± 5.69 0.398
GOT (U/L) 19.7 ± 0.83 25.3 ± 1.09 <0.001
GPT (U/L) 14.8 ± 1.29 25.3 ± 2.44 <0.001
BUN (mg/dL) 12.4 ± 0.52 14.2 ± 0.55 0.028
Creatinine (mg/dL) 0.76 ± 0.03 0.75 ± 0.02 0.957
Mean ± SEM. tested by Student t-test
Table 3 Glucose-related markers in hyperglycemic subjects
Hyperglycemic subjects (n = 50)
TEST (10:1) TEST (15:1) TEST (20:1) Control
insulina 0 min 10.0 ± 0.77 10.4 ± 1.13 10.9 ± 1.39 9.5 ± 0.57
uIU/mL 15 min 15.2 ± 1.41 16.4 ± 1.57 17.5 ± 1.95 21.6 ± 1.75
30 min 24.5 ± 2.31 24.6 ± 2.72 25.2 ± 2.48 33.3 ± 3.19
60 min 30.8 ± 2.80 29.5 ± 3.41 33.7 ± 3.74 35.7 ± 4.46
120 min 19.7 ± 3.59 20.2 ± 3.48 21.7 ± 4.36 16.1 ± 2.74
insulin AUCa (uIU/mLxhr) 47.2 ± 4.69 46.9 ± 5.34 51.8 ± 6.24 53.9 ± 5.58
C-peptidea 0 min 2.43 ± 0.13 2.40 ± 0.14 2.53 ± 0.16 2.42 ± 0.12
(ng/mLxhr 15 min 3.12 ± 0.14 3.21 ± 0.14 3.39 ± 0.17 3.72 ± 0.19
30 min 4.30 ± 0.22 4.31 ± 0.23 4.52 ± 0.20 5.15 ± 0.27
60 min 5.87 ± 0.27 5.89 ± 0.30 6.37 ± 0.29 6.51 ± 0.39
120 min 5.32 ± 0.31 5.48 ± 0.31 5.66 ± 0.32 4.78 ± 0.31
C-peptide AUCa (ng/mLxhr) 9.76 ± 0.44 9.87 ± 0.46 10.46 ± 0.46 10.44 ± 0.53
Mean ± SEM. Tested by ANOVA (Bonferroni)
aAnalyzed after log transformation
Jun et al. Trials  (2016) 17:139 Page 6 of 8
the inhibitory effects of two different concentrations
of xylose (5 and 7.5 g) on postprandial serum glucose
and insulin concentrations in healthy subjects. How-
ever, our study examined the effect of three different
concentration of xylose (2.5, 3.33, and 5 g) on post-
prandial serum glucose and insulin concentrations in
subjects with normal glucose levels and hypergly-
cemia. We focused on the effect of low concentra-
tions of xylose.
Some studies examined whether sucrose drinks with
5 % (w/w) D-xylose exerted beneficial effects on enhan-
cing the glycemic response [18, 19], but the number of
subjects in these studies was too small (n = 10 and n =
13) to define the effect of D-xylose.
The homeostasis of glucose and other glucose-related
metabolites, such as insulin and C-peptide, were the tar-
gets for the prevention of metabolic syndrome, such as
type 2 diabetes and cardiovascular disease [13]. Glucose
absorption in the intestines should be adequately regu-
lated to maintain glycemic homeostasis. Therefore, it is
important that sucrase not rapidly hydrolyze sucrose
into glucose and fructose. The effect of D-xylose oc-
curs via the inhibition of sucrase activity in a non-
competitive manner [12]. Specifically, D-xylose in-
hibits sucrase activity by combining with the inter-
mediate of sucrase and glucose, immediately after
the dissociation of fructose [18].
However, the ability of D-xylose to control the post-
prandial glycemic response may be difficult to sustain
because a large amount of xylose is excreted rapidly in
urine [20]. Significant results in the prevention of the
rapid increase in blood glucose, insulin, and C-peptide
were observed at 15 min and 30 min, but this effect was
not sustained at the later time points of 60 min and
120 min. Blood glucose levels were even higher 120 min
after the consumption of xylose-containing drinks com-
pared to a control drink, which may have occurred be-
cause secretion of the glucose-lowering hormone insulin
was less stimulated by lower levels of serum glucose at
15 min and 30 min. However, xylose still effectively
controlled postprandial glycemic because the AUCs of
glucose, insulin, and C-peptide were significantly smaller
after the consumption of all test drinks containing
xylose.
One limitation of this study is that it evaluated the in-
hibitory effect of xylose on postprandial hyperglycemia
after the intake of sucrose, but not complex carbohy-
drates. Our study period was also very short, and all of
the test products were consumed once weekly. There-
fore, further studies are required to identify how
long-term xylose consumption affects glucose control
and the effect of postprandial glucose on complex
carbohydrates containing xylose (for example, muffins
or sandwiches).
The present study suggests that xylose supplementa-
tion (5, 3.33, and 2.5 g) in drinks exhibits a beneficial ef-
fect on postprandial glycemic response and glucose-
related biomarkers, including insulin and C-peptide
levels, in subjects with normal glucose levels and im-
paired fasting glucose.
Conclusions
We investigated whether D-xylose less than 5 g per 50 g
sucrose exerted beneficial effects on postprandial gly-
cemic control. We found that xylose supplementation
may exert beneficial effects on postprandial glucose me-
tabolism. Notable effects on postprandial glucose, insu-
lin, and C-peptide levels were observed 15 and 30 min
after the consumption of test drinks. Xylose supplemen-
tation may exert a beneficial effect on postprandial gly-
cemic responses in subjects with normal glucose levels
and prediabetes.
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